Pneumococcal 24-Valent -vaccine(Affinivax)

N/A

Report date: 2025/11/07 20:01:05

Base Information

Drug NamePneumococcal 24-Valent -vaccine(Affinivax)
Drug Alias NamePneumococcal MAPS vaccine(Astellas Pharma/ Affinivax)Pneumococcal vaccine(Astellas)Streptococcus pneumoniae MAPS vaccine(Astellas Pharma)MAPS Pneumococcal 24-valent(GSK)MAPS Pneumococcal 24-valent paed(GSK) +[12] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Bacterial vaccineVaccines > Development/production technology > Conjugated vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPneumonia, BacterialPneumococcal Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAffinivax Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcAstellas Pharma IncAffinivax Inc
Active IndicationsN/A
Inactive IndicationsPneumonia, BacterialPneumococcal Infections

Other Information

ATC CodeN/A
Related LinksN/A